4 results about "Stasis Syndrome" patented technology

The invention discloses a marker combination for diagnosing heart failure blood stasis syndrome and application thereof, the marker combination comprises a marker A and a marker B, the marker A is Cr, and the marker B is selected from at least one of PCSK9, AFM and APOC1. The marker combination provided by the invention is applied to clinical diagnosis or auxiliary diagnosis of heart failure blood stasis syndrome patients, has relatively high sensitivity and specificity, and can effectively distinguish the heart failure blood stasis syndrome patients from heart failure non-blood-stasis syndrome patients; reliable basis and practical guidance can be provided for clinical diagnosis and drug treatment of the heart failure blood stasis syndrome, and the accuracy and standardization degree of traditional Chinese medicine syndrome differentiation diagnosis can be improved.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a composition for treating yin deficiency and phlegm stasis syndromes as well as a preparation method and application thereof. The composition is prepared from the following medicinal raw materials: rhizoma bletillae, thunberg fritillary bulb, platycodon grandiflorum, radix stemonae, lily, bryozoatum, radix asteris, pseudo-ginseng, Chinese mahonia stem and liquorice. The preparation method comprises the following steps: (1) adding alcohol into rhizoma bletillae, pseudo-ginseng, Chinese mahonia stem and liquorice, and performing reflux extraction to obtain an alcohol extract and decoction dregs; (2) mixing platycodon grandiflorum, thunberg fritillary bulb, radix stemonae, lily, bryozoatum and radix asteris, adding water, decocting, performing microwave treatment, and filtering to obtain an aqueous extract; (3) mixing the medicine residue and the water extract, performing enzymolysis, decocting, and centrifuging to obtain supernate; and (4) mixing the alcohol extract and the supernate, concentrating and drying to obtain the composition. A specific preparation method is adopted, the effects of active ingredients in the traditional Chinese medicine components can be fully exerted, and the treatment score evaluation on the yin deficiency and phlegm stasis syndrome is remarkably improved.

This invention belongs to the field of traditional Chinese medicine research technology, specifically relating to a traditional Chinese medicine composition for treating coronary heart disease, its preparation method, and its application. The traditional Chinese medicine composition is made from the following raw materials in parts by weight: Astragalus membranaceus 15-30 parts, Trichosanthes kirilowii 15-30 parts, Inula japonica 9-12 parts, Rubia cordifolia 9-12 parts, Ligusticum chuanxiong 9-12 parts, Salvia miltiorrhiza 15-30 parts, Leonurus japonicus 9-15 parts, Aucklandia lappa 6-9 parts, and Amomum villosum 3-6 parts. This traditional Chinese medicine composition has a good therapeutic effect on inflammatory factors in patients with coronary heart disease exhibiting qi deficiency and phlegm stasis syndrome, and no other adverse reactions such as liver or kidney damage have been observed in the patients.

The invention discloses a system for evaluating spleen deficiency and phlegm stasis syndromes of diabetic nephropathy based on combined detection of basophilic granulocytes and total bilirubin and application, and belongs to the technical field of biology. A ZDF (fa / fa) rat model is used, BASO% and TBIL levels are quantitatively detected, a modernization biology evaluation system capable of simultaneously reflecting DKD'spleen deficiency 'and'phlegm stasis' core pathogenesis is provided for the first time, and the technical problem that objective and quantitative traditional Chinese medicine syndrome evaluation indexes are lacked in the existing DKD model research field is solved. The method specifically comprises the following steps: associating two indexes belonging to an immune system and a metabolic system for the first time to form a brand-new collaborative evaluation combination, and overcoming the limitation of single index evaluation; a quantifiable and repeatable operation method is provided, and a key tool is provided for traditional Chinese medicine mechanism research and new drug research and development of DKD; traditional Chinese medicine syndromes and modern medical indexes are organically combined, and modernization and internationalization development of traditional Chinese medicine is promoted.